clinical trial · NCT05489614
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Amgen·phase1·completed·n = 33
Renal ImpairmentOlpasiran
brief summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with normal renal function and participants with various degrees of renal impairment.
started
Sep 13, 2022
primary completion
Oct 24, 2023
completion
Dec 19, 2023
last updated
Nov 26, 2025
official title
A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Subjects With Normal Renal Function and Subjects With Various Degrees of Renal Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol